Ana Gómez-Bastero Fernández

Dr. Ana Gómez-Bastero Fernández

orcid

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 May 2022 in Journal of Asthma and Allergy
Verified
Journal Article
Open access
PDF file
AFAna Gómez-Bastero Fernández
Ana Gómez-Bastero Fernández
JGJuan Francisco Medina Gallardo
Juan Francisco Medina Gallardo
JRJulio Delgado Romero
Julio Delgado Romero
AFAuxiliadora Romero Falcón
Auxiliadora Romero Falcón
CBCristina Benito Bernáldez
Cristina Benito Bernáldez
FAFrancisco Javier Alvarez-gutierrez
Francisco Javier Alvarez-gutierrez
Purpose: Benralizumab is a monoclonal antibody that targets the α subunit of the IL-5 receptor. Clinical trials have demonstrated the efficacy of this agent with respect to lung function and symptom control in patients with refractory eosinophilic asthma. However, few studies have evaluated the efficacy of benralizumab after switching previous treatment with other monoclonal antibodies. Patients and Methods: We performed a multicenter retrospective study under conditions of daily clinical practice. The study population comprised consecutively included patients with severe refractory eosinophilic asthma whose initial treatment with omalizumab or mepolizumab was switched to benralizumab. Patients were evaluated at 4 and 12 months after starting treatment with benralizumab. We analyzed asthma control, number of severe exacerbations, corticosteroid cycles, visits to the emergency department, and hospital admissions, as well as lung function. Similarly, we evaluated the response to treatment according to previously established criteria. Results: We evaluated 40 patients who switched from omalizumab (n=16) or mepolizumab (n=24) to benralizumab. The reasons for switching were lack of response in 30 cases, adverse effects in 9, and patient request in 1. Switching was followed by a significant decrease in the number of exacerbations, visits to the emergency department, and corticosteroid cycles, as well as improved ACT both at 4 and 12 months. However, no significant improvement in lung function was observed. Asthma control (including complete response and control) was achieved in 55% of patients (n=22) at 12 months. Specifically, a complete response was achieved in 30% of patients at 12 months (66.7% switching from omalizumab and 33.3% from mepolizumab). Conclusion: Patients diagnosed with severe refractory eosinophilic asthma who experience a partial response with omalizumab or mepolizumab could benefit from switching to benralizumab. This approach can reduce the number of exacerbations, visits to the emergency department, and corticosteroid cycles and improve control of asthma.

13 February 2025 in Journal of Asthma
Verified
Journal Article
Open access
Eva María Martínez PérezEva María Martínez Pérez
Eva María Martínez Pérez
CPCelia Pinedo-Sierra
Celia Pinedo-Sierra
LMLuis Puente MAestu
Luis Puente MAestu
MMMariana Muñoz-Esquerre
Mariana Muñoz-Esquerre
AFAna Gómez-Bastero Fernández
Ana Gómez-Bastero Fernández
SQSantiago Quirce
Santiago Quirce
Asthma and severe asthma are problems affecting all age groups, but asthma is frequently undiagnosed in the elderly, due to the poor perception of airflow limitation, lack of fitness, and presence of multiple comorbidities.Even so, the proportion of patients with severe asthma aged ≥65 is significant, and data on efficacy of asthma medications in the elderly are sometimes limited. We report here the effectiveness and safety of mepolizumab (an IL-5 inhibitor) in elderly (≥ 65 years) patients. The REDES study was an observational, multicenter study of the effectiveness and safety of mepolizumab 100mg SC every 4 weeks in 318 severe asthma patients in Spain. This post-hoc analysis compares the effectiveness and safety of patients ≥65 years old to patients <65 years after 12 months of mepolizumab treatment. 27% of patients were ≥65 years old, compared with 73% of patients <65 years. Elderly patients showed a trend towards less frequent comorbid nasal polyps (p = 0.06) and a lower proportion of atopic sensitization (as detected by prick test or specific IgE) (p = 0.02). Similar improvements were noted in ACT score (p < 0.0001), comparable exacerbation reductions (p < 0.0001) and lung function parameters (p < 0.04 in elder group and p < 0.0001 in younger elder group), although an apparent greater reduction of OCS daily dose was observed in elder patients (p = 0.0002). No new safety signals were reported in the elderly population. This study further supports mepolizumab as an effective and well tolerated therapy in the difficult to treat population of elderly patients with severe asthma.

Verified
Journal Article
Open access
PDF file
IGIsmael García-Moguel
Ismael García-Moguel
JCJUAN AGUERO CALVO
JUAN AGUERO CALVO
BDBetancor Diana
Betancor Diana
JGJosé Ángel Carretero Gracia
José Ángel Carretero Gracia
RCRocío Magdalena Díaz Campos
Rocío Magdalena Díaz Campos
JGJose Luis Velasco Garrido
Jose Luis Velasco Garrido
Background: The GALERNA study is a retrospective real-world observational study conducted across 21 hospitals in Spain, aiming to evaluate long-term clinical benefits and adherence to benralizumab in 255 adult patients with severe eosinophilic asthma (SEA) over a follow-up period of up to 144 weeks. Objectives: Primary objectives focused on assessing adherence to benralizumab, while secondary objectives included the description of severe asthma exacerbation rates, systemic corticosteroid (SCS) use, persistence to benralizumab, lung function, asthma control, and the proportion of patients achieving super-response or clinical remission. Data were collected at baseline (48 weeks prior to benralizumab initiation/index date), follow-up 1 (FUP1) (0–48 weeks), FUP2 (49–96 weeks), and FUP3 (97–144 weeks) after the index date. Results: At baseline, patients demonstrated a substantial disease burden characterised by impaired lung function, poorly controlled asthma, and frequent severe exacerbations. The results indicated high adherence rates to benralizumab, with 92.9% of patients receiving each of the prescribed doses of benralizumab at week 48 and 70.6% at week 144. Patients showed substantial and sustained clinical improvements, with a reduction in the proportion of individuals presenting at least one severe exacerbation from baseline to FUP3 and a 74% decrease in SCS use for the same period. Lung function also improved, with the proportion of patients achieving pre-bronchodilator FEV1 ≥ 80% rising to 52% at 144 weeks. Furthermore, mean Asthma Control Test (ACT) scores increased to 20.5, with 68.5% of patients achieving well-controlled asthma (ACT ≥ 20). By the end of the study, 63.6% of patients achieved super-response and 39.1% showed clinical remission, with an overall benralizumab persistence of 79.8% during all follow-up periods. Conclusions: The GALERNA study provides compelling real-world evidence that benralizumab affords marked and sustained clinical benefits together with high long-term adherence in Spanish SEA patients, reinforcing its usefulness as a long-term therapeutic option in routine clinical practice.

1 September 2020
Verified
Journal Article
Closed access
MCMonica Climente-Marti
Monica Climente-Marti
PAPilar Ausín-Herrero
Pilar Ausín-Herrero
NCNuria Carballo-Martínez
Nuria Carballo-Martínez
VMVICENTE MERINO-BOHÓRQUEZ
VICENTE MERINO-BOHÓRQUEZ
AFAna Gómez-Bastero Fernández
Ana Gómez-Bastero Fernández
VLVíctor Manuel López-García
Víctor Manuel López-García

15 October 2026 in Respiratory Research
Verified
Journal Article
Open access
PDF file
APAlicia Padilla-Galo
Alicia Padilla-Galo
CRCarlos Martinez Rivera
Carlos Martinez Rivera
ATA. Trisán-Alonso
A. Trisán-Alonso
AFAna Gómez-Bastero Fernández
Ana Gómez-Bastero Fernández
AMAlvaro Martinez Mesa
Alvaro Martinez Mesa
MAMARINA BLANCO APARICIO
MARINA BLANCO APARICIO
Eosinophilic granulomatosis with polyangiitis (EGPA) is a rare systemic inflammatory disease in which severe asthma frequently represents the predominant c

2 September 2026 in World Journal of Otorhinolaryngology - Head and Neck Surgery
Verified
Journal Article
Open access
Diego Marcelo ContiDiego Marcelo Conti
Diego Marcelo Conti
ECEduardo Javier Correa
Eduardo Javier Correa
Alfonso Del Cuvillo BernalAlfonso Del Cuvillo Bernal
Alfonso Del Cuvillo Bernal
JAJosé D. Abdullatif
José D. Abdullatif
FAFrancisco Javier Alvarez-gutierrez
Francisco Javier Alvarez-gutierrez
Juan Maza-SolanoJuan Maza-Solano
Juan Maza-Solano
Background: Chronic respiratory diseases impose a large global burden of morbidity, mortality, and cost. The concept of a global airway has become increasingly supported by epidemiologic, mechanistic, and clinical evidence. However, clinical care often remains fragmented between ear, nose, and throat (ENT), allergy, and pulmonology. Methods: A multidisciplinary expert panel composed of allergists, pulmonologists, and otolaryngologists from multiple tertiary care centres was convened. Experts were selected using predefined criteria encompassing clinical experience, academic output, geographic and institutional diversity, and gender balance. The panel performed a structured synthesis of current international guidelines and high‐impact literature, using a modified Delphi consensus process over 3 rounds, with a predefined agreement threshold of ≥ 80% to define the scope of diseases, diagnostic approach, and interdisciplinary care model. Results: The Global Airways Unit (GAU) framework prioritizes multidisciplinary teamwork, early detection of comorbidities, phenotype‑directed investigations, streamlined imaging, and assignment of a lead specialty with scheduled follow‑up. Expected benefits include earlier diagnosis, improved disease control and quality of life (QoL), reduced duplication of testing, and potential cost‑savings for patients and health systems. Conclusions: The GAU operationalises the unified airway hypothesis into a reproducible clinical model. We propose the formation of a GAU to coordinate the management of patients with inflammatory airway diseases. Prospective real‑world evaluation of GAU implementation is the next critical step to validate clinical and economic outcomes.